MeSH tree: D12.644.548.275
The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. ...
Jul 22, 2026
0
26
Anyone who has bought medicine online may have wondered whether what arrived in the mail was really what they had paid for. They are not alone. A recent global survey found that around 60% of people fear their medicines could ...
Jul 22, 2026
0
4
Despite the end of federal shortages of popular GLP-1 weight-loss medications, the market for compounded alternatives remains strong—and some patients may unknowingly be receiving products from pharmacies with concerning ...
Jul 17, 2026
0
6
Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds ...
Jul 16, 2026
0
5
Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City, Mexico, hosted by the World ...
Jul 15, 2026
0
21
For many people living with obesity, newer weight-loss medicines such as Wegovy and Mounjaro have been transformative. These drugs are often grouped under the label GLP-1 medicines because they mimic hormones released after ...
Jul 10, 2026
0
6
Weight-loss jabs are the latest craze for shedding a few pounds. Their effect has been dramatic, with drugs such as Ozempic and Wegovy (semaglutide) causing users to lose up to 15% of their body fat on average.
Jun 17, 2026
0
7
A new article published in Globalization and Health warns that the rapid rise of GLP-1 weight-loss drugs in high-income countries could have unintended consequences for food environments in low- and middle-income countries.
Jun 16, 2026
0
4
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and colleagues explored the full range of responses ...
Jun 16, 2026
0
18
One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting ...
Jun 15, 2026
0
3
